Board summary
Key figures
36,597
Registered population
57.8% aged 18–64
20.3%
Aged 65+
ICB 14.9% · England 17.9%
5.7%
In IMD quintile 1
ICB 40.7% · England 21.0%
~2,231
Core20 residents (est.)
Resident basis; registered basis ~2,226 · see page 3
5,997
Hypertension register
+5.25% in 3 yrs · England +5.60%
349
SMI register
10.4% of Stockport (LAD)'s
526
COPD register
Reviews +0.22% in 3 yrs
Forecast to 2030
6,861
Hypertension patients, 2030
+864 on today
68.3%
QRISK ≥20% on statins, 2030
+2.78pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Deprivation concentrates at Cheadle Medical Practice.
Cheadle Medical Practice holds a 15.1% Core20 share (1,801 estimated patients) vs 0.0% at Gatley Medical Centre, alongside a 14.4 pp phone access range.
Heart failure and asthma reviews trail comparators.
Heart failure reviews fell 7.2% over 2023 to 2025 to 67.1% (England 78.5%), and about 840 asthma patients lack a review, which may reflect.
Hypertension control and SMI checks exceed England.
Hypertension treatment to target reaches 72.8% (England 70.3%), BP monitoring is 92.2% (England 90.0%), and SMI annual BP checks reach 87.9% (England 83.4%).
Population, age and ethnicity
A dual-peaked age profile is consistent with higher youth and older adult demand
Cheadle Network PCN registers 36,597 patients with a dual-peaked age profile. Children aged 0-17 comprise 22.0% (8,044 patients), exceeding Stockport (LAD) (19.7%), NHS Greater Manchester Integrated Care Board (21.8%), and England (19.6%). Older adults aged 65+ represent 20.3% (7,419 patients), above Stockport (LAD) (19.7%), the ICB (14.9%), and England (17.9%). Working-age adults (18-64) account for 57.8% (21,134 patients). Census-recorded Gypsy or Irish Traveller residents are 0.0% and Roma residents 0.1%. Observation periods were not supplied for list counts.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Stockport LA) | 2,072 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Stockport LA) | 919 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Stockport LA) | 23.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation averages decile 7.3 but Core20 share reaches 15.1% at Cheadle Medical Practice
Average IMD decile is 7.3 (Stockport (LAD) 6.4, England 5.5). The Core20 share—patients in England's most deprived 20%—is 5.7% (England 21.0%). Deprivation is concentrated: Cheadle Medical Practice holds 15.1% Core20 share (estimated 1,801 patients), whereas Gatley Medical Centre records 0.0% (Finney Lane Surgery 3.5%, Heald Green Health Centre 2 2.4%). Weighted practice share (6.1%) differs by 0.34 pp from the PCN rate, and resident estimates (about 2,200) use a different base; periods are unstated. Outreach should focus primarily where Core20 volume concentrates.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
349
SMI register
0.96% recorded prevalence
208
Learning disability register
0.57% recorded prevalence
11
Care homes, 527 beds
In the PCN catchment
9.5%
Provide unpaid care
Stockport (LAD), Census 2021
Severe mental illness records 349 patients (1.0%) and learning disabilities 208 (0.6%), both matching England (1.0% and 0.6%). In the catchment area, 11 care homes contain 527 beds, though bed capacity does not establish resident numbers. Stockport borough context includes 48 rough sleepers in 2025 and an estimated ceiling of 3,477 unpaid carers.
Severe mental illness: physical health checks
SMI blood pressure checks reached 87.9% (England 83.4%) and BMI recording reached 86.1% (England 82.1%). However, BMI recording fell 0.7 pp over 2023 to 2025 (England +5.1 pp), and Cheadle Medical Practice recorded 76.0%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,997
Hypertension register
+5.25%
Register growth, 3 yrs
Stockport (LAD) +4.99% · England +5.60%
+2.35pp
BP control, under 80
≤140/90 · +2.44pp aged 80+
+864
More patients by 2030
Forecast 6,861 (18.23%)
Hypertension case-finding and control
Recorded hypertension prevalence is 16.5% across 5,997 patients, compared with 16.2% in Stockport (LAD), 14.4% in the ICB, and 15.2% in England. Blood pressure checks reach 92.2% (England 90.0%) and treatment to target reaches 72.8% (England 70.3%). Across 477 heart failure patients (prevalence 1.3%), annual reviews including functional capacity assessment fell 7.2% over 2023 to 2025 (England +8.7%) to 67.1%, trailing Stockport (LAD) (79.3%), the ICB (80.0%), and England (78.5%). Denominators include personalised care adjustments, and crude prevalence does not establish unmet need. Hypertension management exceeds national benchmarks, but heart failure review rates trail all comparators, so prioritising structured heart failure recalls is the key clinical opportunity.
Lipids and statins
Lipid therapy for QRISK ≥ 20% reaches 62.3%, below Stockport (LAD) (64.8%), the ICB (67.0%), and England (63.6%). Primary-prevention statins in diabetes fell 2.8% over 2023 to 2025 (England +2.1%) to 70.6% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than benchmarks imply, making targeted primary-prevention recall the operational priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 68,587 | £2.20 | £1.94 | £1.86 | £150,891 |
| Cardiovascular (all), 2025 | 96,838 | £2.97 | £3.15 | £3.33 | £287,609 |
In 2026, 68,587 items of lipid-regulating drugs were prescribed (spend £150,891) at £2.20 per item, exceeding Stockport (LAD) (£1.99), the ICB (£1.94), and England (£1.86). The PCN spent £23,320 more than at England's unit cost across 68,587 items. This metric reflects unit cost rather than efficiency; formulary reviews would test prescribing choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−1.26%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−3.50%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.4% (526 patients), below England (1.9%) and Stockport (LAD) (2.1%), and fell 6.5% over 2023 to 2025 while England grew +2.6% (unadjusted gap +167 to +259 patients). COPD reviews reach 77.4% (England 76.4%). Asthma prevalence is 7.1% (2,406 patients), but annual reviews fell 1.3% over 2023 to 2025 to 65.1% (England 65.7%), leaving about 840 patients unreviewed. Youth asthma second-hand smoke recording is 72.1% (England 78.8%). Register audits would test potential case-finding gaps.
Cancer register and children's immunisation
Cancer prevalence is 4.5% (1,655 patients), above England (3.8%) and Stockport (LAD) (4.4%), though growth (+5.2%) lagged England (+9.0%) over 2023 to 2025. In Q1 2025/26, 6-in-1 coverage at 12 months is 88.9% (below the 95.0% target by 6.1 pp). At age 5, MMR dose 1 is 95.6% and dose 2 is 93.0%, while 4-in-1 booster coverage is 86.8% (below the 95.0% target by 8.2 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, across NHS Greater Manchester ICB, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), with a distance of -19.4 pp to the 75.0% national ambition by 2028. Staging coverage was 70.8% (11,679 of 16,492 cancers; England 67.0%). Reaching the ambition requires about 2,270 additional early-stage cases annually across the ICB. While ICB staging reflects wider system performance rather than PCN delivery, PCN cervical screening coverage is 74.2% (Stockport (LAD) 75.9%, England 66.8%), after falling 7.2% over 2023 to 2025 (England -1.0%). Slower screening uptake could delay early cancer diagnosis; recall audits would test local booking barriers.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), provider Manchester University NHS Foundation Trust achieved 72.8% on the cancer 62-day referral to treatment standard (Stockport NHS Foundation Trust 74.7%, Northern Care Alliance NHS Foundation Trust 78.6%, NHS Greater Manchester Integrated Care Board 75.7%, England 71.2%), with a distance of -12.2 pp to the 85.0% standard. Cancer 28-day faster diagnosis reached 80.1% (Stockport NHS Foundation Trust 83.2%, ICB 79.5%, England 79.3%), exceeding the 75.0% standard by 5.1 pp. Diagnostic waits of 6+ weeks at the trust reached 14.7% for CT and 11.7% for MRI (Stockport NHS Foundation Trust 2.9% and 1.4%).
| Pathways within standard (%) | Manchester | Stockport | Northern Care Alliance | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 83.21 | 75.20 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 97.39 | 94.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 74.67 | 78.65 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Stockport | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 11.68 | 1.41 | 5.09 | 21.40 |
| CT | 14.66 | 2.93 | 4.10 | 9.92 |
| Echocardiography | 4.91 | 17.46 | 31.48 | 28.48 |
| Colonoscopy | 4.51 | 5.53 | 40.04 | 30.83 |
| Gastroscopy | 29.35 | 5.31 | 36.48 | 29.02 |
| All 15 DM01 tests | 8.98 | 14.08 | 15.71 | 23.14 |
| Community services activity | Stockport residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 57,085 | 573,310 |
| Referrals | 10,690 | 94,470 |
| Patients with a contact | 16,950 | 183,535 |
Community services (residents of Stockport), Jun 2026 (provisional). In Jun 2026 (provisional), 60.6% of community contacts among Stockport borough residents were with adults aged 65+ (34,585 of 57,085 contacts). This reflects wider borough community service utilisation rather than PCN-level activity, as PCN-specific community contacts were not captured.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Gatley | 148 | 0.0 | 68.3% | 70.1% | 87.1% |
| Finney Lane | 109 | 3.5 | 58.3% | 84.3% | 85.4% |
| Cheadle Medical | 102 | 15.1 | 53.9% | 66.3% | 78.8% |
| Heald Green 2 | 130 | 2.4 | 55.7% | 72.2% | 78.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eighteen of 25 tracked measures trail England over three years, led by reviews
Over 2023 to 2025, 18 of 25 tracked measures trailed England's change. The widest lags were heart failure reviews, falling 7.2% while England rose +8.7% (trailing England by 15.9 points), and COPD prevalence, falling 6.5% while England grew +2.6% (trailing by 9.15 points). Asthma reviews also fell 1.3% (England +4.4%). Relative strengths include breast screening coverage rising +9.9% (England +8.4%), blood pressure control for patients aged 80+ rising +3.1% (England +2.2%), and psychosis alcohol recording increasing +6.2 pp (England +5.4 pp). Slower review growth may reflect recall gaps, which register audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD register
Cervical screening
BMI record (SMI)
Asthma reviews
Breast screening (53-70)
BP control, 80+
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Stockport (LAD) | Asset | PCN | Stockport (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (527 beds) | n/a | Schools (catchment) | 49 | n/a |
| Children's centres | no data | 2 | Places of worship | 27 | 135 |
| Libraries | 2 | 12 | Food banks (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 12 | 61 | Primary academies | 2 | 23 |
| Special schools | 3 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 65.1% (England 65.7%, ICB 66.2%, Stockport (LAD) 63.4%) after falling 1.3% (0.8 pp) over 2023 to 2025, leaving about 840 of 2,406 patients unreviewed. For discussion: run a single-template asthma recall with flexible or school-holiday slots and inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD case-finding and spirometry audit
COPD prevalence is 1.4% (526 patients vs England 1.9%, Stockport (LAD) 2.1%, ICB 2.3%) after falling 6.5% over 2023 to 2025; unadjusted gap is +167 to +259 across 36,597 patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Heart failure and lipid recall
Heart failure reviews fell 7.2% over 2023 to 2025 to 67.1% (England 78.5%, Stockport (LAD) 79.3%; 477 register, 1.3%). QRISK ≥ 20% lipid therapy is 62.3% (England 63.6%) and diabetes statins 70.6% (England 73.2%). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI annual check recall (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Heart failure annual review audit (p5) | Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
| Preschool booster recall audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD case-finding and spirometry audit (p12) | COPD register · COPD: QOF prevalence · Registered population | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Heart failure and lipid recall (p12) | Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
